97. Ulcerative colitis Clinical trials / Disease details
Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05121402 (ClinicalTrials.gov) | December 30, 2022 | 5/11/2021 | Safety and Efficacy Study of TLL018 in the Treatment of Ulcerative Colitis | A Phase 2 Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of TLL018 for Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis | Ulcerative Colitis | Drug: TLL018;Other: Placebo | TLL Pharmaceutical, LLC | NULL | Withdrawn | 18 Years | 75 Years | All | 0 | Phase 2 | United States |